Renin-Angiotensin System

• 

  Subject Areas on Research

  • 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. 
  • A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19. 
  • A genetic approach for studying the physiology of the type 1A (AT1A) angiotensin receptor. 
  • A new cardiac MASTer switch for the renin-angiotensin system. 
  • A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. 
  • A randomized intervention study to evaluate the effect of calcitriol therapy on the renin-angiotensin system in diabetes. 
  • A reappraisal of loop diuretic choice in heart failure patients. 
  • A role for the thromboxane receptor in L-NAME hypertension. 
  • ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. 
  • AT(1) receptors and control of blood pressure: the kidney and more.. 
  • AT1 Angiotensin receptors-vascular and renal epithelial pathways for blood pressure regulation. 
  • AT1A angiotensin receptors in the renal proximal tubule regulate blood pressure. 
  • Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. 
  • Adult renal mesenchymal stem cell-like cells contribute to juxtaglomerular cell recruitment. 
  • Aldosterone as a mediator of severity in retinal vascular disease: Evidence and potential mechanisms. 
  • Angiotensin II Short-Loop Feedback: Is There a Role of Ang II for the Regulation of the Renin System In Vivo? 
  • Angiotensin II and aldosterone in retinal vasculopathy and inflammation. 
  • Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. 
  • Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. 
  • Angiotensin as local modulating factor in ventricular dysfunction and failure due to coronary artery disease. 
  • Angiotensin converting enzyme in renal ontogeny: hypothesis for multiple roles. 
  • Angiotensin receptors in the kidney and vasculature in hypertension and kidney disease. 
  • Angiotensin-II-receptors: new targets for antihypertensive therapy. 
  • Antihypertensive Drugs and Cancer Risk. 
  • Apparent treatment-resistant hypertension and chronic kidney disease: another cardiovascular-renal syndrome? 
  • Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19. 
  • Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. 
  • Association of gene variants of the renin-angiotensin system with accelerated hippocampal volume loss and cognitive decline in old age. 
  • Autocrine-paracrine mechanisms of vascular myocytes in systemic hypertension. 
  • Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. 
  • Beta2-adrenergic receptor genotype affects the renin-angiotensin-aldosterone system response to the Dietary Approaches to Stop Hypertension (DASH) dietary pattern. 
  • Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. 
  • C-C Motif Chemokine 5 Attenuates Angiotensin II-Dependent Kidney Injury by Limiting Renal Macrophage Infiltration. 
  • Cardiac renin-angiotensin system. Molecular and functional aspects. 
  • Cardiovascular phenotype of mice lacking all three subtypes of angiotensin II receptors. 
  • Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. 
  • Characterization and Functional Phenotyping of Renal Immune Cells via Flow Cytometry. 
  • Circulating versus local renin-angiotensin system in cardiovascular homeostasis. 
  • Classical Renin-Angiotensin system in kidney physiology. 
  • Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. 
  • Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activated intrarenal renin-angiotensin system is correlated with high blood pressure in humans. 
  • Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality. 
  • Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. 
  • Compensatory response to hemorrhage in conscious dogs on normal and low salt intake. 
  • Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial. 
  • Contributions of neuroendocrine and local autocrine-paracrine mechanisms to the pathophysiology and pharmacology of congestive heart failure. 
  • Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. 
  • Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System. 
  • Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. 
  • Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. 
  • Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. 
  • Developmental renin expression in mice with a defective renin-angiotensin system. 
  • Diagnosis and management of renovascular hypertension. 
  • Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. 
  • Direct Actions of AT1 (Type 1 Angiotensin) Receptors in Cardiomyocytes Do Not Contribute to Cardiac Hypertrophy. 
  • Disentangling the Relationships Between the Renin-Angiotensin-Aldosterone System, Calcium Physiology, and Risk for Kidney Stones. 
  • Dissociation of the prostaglandin and renin angiotensin systems during captopril therapy for chronic congestive heart failure secondary to coronary artery disease. 
  • Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. 
  • Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. 
  • Dual renin-angiotensin system blockade in heart failure. 
  • Effect of captopril on the release of the components of the renin-angiotensin system into plasma and lymph. 
  • Effect of renin-angiotensin system blockade on the expression of the angiotensinogen gene and induction of hypertrophy in rat kidney proximal tubular cells. 
  • Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. 
  • Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study. 
  • Emerging Viral Infections and the Potential Impact on Hypertension, Cardiovascular Disease, and Kidney Disease. 
  • Emerging role of the tissue renin-angiotensin systems in congestive heart failure. 
  • Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. 
  • Endothelial renin-angiotensin pathway. Adrenergic regulation of angiotensin secretion. 
  • Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins. 
  • Epidemiology of cardiorenal syndrome. 
  • Essential role(s) of the intrarenal renin-angiotensin system in transforming growth factor-beta1 gene expression and induction of hypertrophy of rat kidney proximal tubular cells in high glucose. 
  • Evidence for the existence of renin in the heart. 
  • Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. 
  • Evolving concepts of the intrarenal renin-angiotensin system in health and disease: contributions of molecular biology. 
  • Evolving concepts of the renin-angiotensin system. Focus on renal and vascular mechanisms. 
  • Exploring type I angiotensin (AT1) receptor functions through gene targeting. 
  • Expression of renin-angiotensin system and extracellular matrix genes in cardiovascular cells and its regulation through AT1 receptor. 
  • Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study. 
  • Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003. 
  • From confusion to clarity: RAS blockade in patients hospitalized with COVID-19. 
  • Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. 
  • Gene targeting in physiological investigations: studies of the renin-angiotensin system. 
  • Gene-targeting studies of the renin-angiotensin system: mechanisms of hypertension and cardiovascular disease. 
  • Genetic manipulation of the renin-angiotensin system. 
  • Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? 
  • Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. 
  • Granulocyte-angiotensin system. Identification of angiotensinogen as the plasma protein substrate of leukocyte cathepsin G. 
  • Hemodynamic effects of vasorelaxant compounds in mice lacking one, two or all three angiotensin II receptors. 
  • How low can you go? Achieved blood pressure and cardiovascular outcomes. 
  • Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. 
  • Immortalized rat proximal tubule cell lines expressing components of the renin-angiotensin system. 
  • Immunologic Effects of the Renin-Angiotensin System. 
  • Impact of Angiotensin Type 1A Receptors in Principal Cells of the Collecting Duct on Blood Pressure and Hypertension. 
  • Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. 
  • Impact of renin-angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis of from the PARTNER 2 trial and registries. 
  • Implications of local angiotensin production in cardiovascular physiology and pharmacology. 
  • Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. 
  • In hypertension, the kidney breaks your heart. 
  • In hypertension, the kidney rules. 
  • In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. 
  • Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock. 
  • Interactions Between the Immune and the Renin-Angiotensin Systems in Hypertension. 
  • Interleukin-1 Receptor Activation Potentiates Salt Reabsorption in Angiotensin II-Induced Hypertension via the NKCC2 Co-transporter in the Nephron. 
  • Is renin a factor in the etiology of essential hypertension? 
  • Kidney in hypertension: guyton redux. 
  • Large conduit arteries in hypertension: role of the vascular renin-angiotensin system. 
  • Learning whether to subtract beta-blockers: it's about time. 
  • Liver X receptors alpha and beta regulate renin expression in vivo. 
  • Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. 
  • Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. 
  • Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial. 
  • Megalin binds and internalizes angiotensin-(1-7). 
  • Mesenchymal stem cells differentiate into renin-producing juxtaglomerular (JG)-like cells under the control of liver X receptor-alpha. 
  • Modulation of the BP response to diet by genes in the renin-angiotensin system and the adrenergic nervous system. 
  • Molecular and physiological aspects of tissue renin-angiotensin system: emphasis on cardiovascular control. 
  • Molecular biology and pathophysiology of the intrarenal renin-angiotensin system. 
  • Molecular biology of hypertension. 
  • Molecular biology of renal injury: emphasis on the role of the renin-angiotensin system. 
  • Molecular biology of the renin-angiotensin system. 
  • Molecular biology techniques and their applicability to the study of diabetes and hypertension: the renin-angiotensin system as an example. 
  • Molecular mechanism of fibronectin gene activation by cyclic stretch in vascular smooth muscle cells. 
  • Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. 
  • Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses. 
  • Neurohumoral mechanisms in heart failure: role in pathogenesis, therapy, and drug tolerance. 
  • Non-traditional systemic treatments for diabetic retinopathy: an evidence-based review. 
  • Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. 
  • Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. 
  • Pathophysiology of experimental renovascular hypertension. 
  • Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. 
  • Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system. 
  • Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. 
  • Plasma renin testing to guide antihypertensive therapy. 
  • Possible prorenin activating mechanisms in the blood vessel wall. 
  • Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. 
  • Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Progress in angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses. 
  • Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. 
  • Quinapril--a new angiotensin-converting enzyme inhibitor: an overview. 
  • RAAS Inhibition to Prevent GI Bleeding: Another Reason to Do the Right Thing. 
  • Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure. 
  • Rat proximal tubule cell line transformed with origin-defective SV40 DNA: autocrine ANG II feedback. 
  • Recent advances involving the renin-angiotensin system. 
  • Regulation of intrarenal and circulating renin-angiotensin systems in severe heart failure in the rat. 
  • Relationship of cardiac chamber volume to baroreflex activity in normal humans. 
  • Renal denervation attenuates NADPH oxidase-mediated oxidative stress and hypertension in rats with hydronephrosis. 
  • Renal effects of angiotensin-converting enzyme inhibition in cardiac failure. 
  • Renin synthesis by canine aortic smooth muscle cells in culture. 
  • Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. 
  • Renin-angiotensin system and renal circulation in clinical congestive heart failure. 
  • Renin-angiotensin system gene expression in post-transplant hypertension predicts allograft function. 
  • Renin-angiotensin system inhibition in advanced chronic kidney disease: how low can the kidney function go? 
  • Renin-angiotensin system stimulates respiration during acute hypotension but not during hypercapnia. 
  • Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle. 
  • Renin-angiotensin-aldosterone system in nephrotic syndrome. 
  • Renovascular hypertension. 
  • Renovascular hypertension: an update on pathophysiology, diagnosis and treatment. 
  • Report of the Joint Nomenclature and Standardization Committee of the International Society of Hypertension, American Heart Association and the World Health Organization. 
  • Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices. 
  • Short- and long-term determinants of cardiovascular function and therapy: contributions of circulating and tissue renin-angiotensin systems. 
  • Significance of the vascular renin-angiotensin pathway. 
  • Soluble ACE2 Is Filtered into the Urine. 
  • Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. 
  • Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD). 
  • Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria. 
  • Targeting genes in the renin-angiotensin system. 
  • Targeting heart failure therapeutics: a historical perspective. 
  • Temperature-sensitive SV40 immortalized rat proximal tubule cell line has functional renin-angiotensin system. 
  • The Association Between Beta-blocker and Renin-Angiotensin System Inhibitor Use After Heart Failure With Reduced Ejection Fraction Hospitalization and Outcomes in Older Patients. 
  • The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. 
  • The feedback regulation of angiotensinogen production by components of the renin-angiotensin system. 
  • The genetic determinants of renal impairment following cardiac surgery. 
  • The inextricable role of the kidney in hypertension. 
  • The kidney and hypertension: lessons from mouse models. 
  • The kidney and hypertension: novel insights from transgenic models. 
  • The neurohormonal network in the RAAS can bend before breaking. 
  • The past, present and future of renin-angiotensin aldosterone system inhibition. 
  • The renin-angiotensin system and diabetic nephropathy. 
  • The renin-angiotensin system and prevention of age-related functional decline: where are we now? 
  • The renin-angiotensin system: it's all in your head. 
  • The renin-angiotensin-aldosterone system: a specific target for hypertension management. 
  • The role of macrophages in hypertension and its complications. 
  • The role of type 1 angiotensin receptors on T lymphocytes in cardiovascular and renal diseases. 
  • Tissue angiotensin system in cardiovascular medicine. A paradigm shift? 
  • Tissue renin-angiotensin system in myocardial hypertrophy and failure. 
  • Tissue renin-angiotensin system: physiologic and pharmacologic implications. Introduction. 
  • Transgenic mice as a tool to study the renin-angiotensin system. 
  • Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. 
  • Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 
  • Tumor necrosis factor-α produced in the kidney contributes to angiotensin II-dependent hypertension. 
  • Type 2 angiotensin II receptor expression in human renal allografts: an association with chronic allograft nephropathy. 
  • Update on Chronic Kidney Disease Mineral and Bone Disorder in Cardiovascular Disease. 
  • Use of renin-angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines-Coronary Artery Disease Program. 
  • Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. 
  • Vascular angiotensin pathways: a new therapeutic target. 
  • Vascular remodeling--the emerging paradigm of programmed cell death (apoptosis): the Francis B. Parker lectureship. 
  • Vascular renin--a consensus view. 
  • Vascular renin-angiotensin system and vascular protection. 
  • Vascular renin-angiotensin system in hypertension. New insights into the mechanism of action of angiotensin converting enzyme inhibitors. 
  • Vascular renin-angiotensin: a possible autocrine or paracrine system in control of vascular function. 
  • Vascular wall renin-angiotensin pathway in control of the circulation. A hypothesis. 
  • Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. 
  • What can knockout mice contribute to an understanding of hypertension? 
  • Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Mentz, Robert John, Associate Professor of Medicine, Medicine, Cardiology
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Sparks, Matthew A., Associate Professor of Medicine, Medicine, Nephrology